Anti-MHCII [VHH7]
Catalogue Number: AB04080-23.159-BT-ABA
| Manufacturer: | Vector Laboratories, Inc (ABA) |
| Type: | VHH Nanobodies |
| Alias: | class II MHC; class II histocompatibility antigen |
| Shipping Condition: | Blue Ice |
| Storage Condition: | 2-8°C |
| Unit(s): | 1 mg |
| Host name: | Rabbit |
| Clone: | VHH7 |
| Isotype: | IgG |
| Immunogen: | The original antibody was generated by immunizing an alpaca with intact, unfractionated mouse splenocytes seven times. |
| Application: | FC, IF, IP, Blk, InVitroA, InVivoA, SPR, Img |
Additional Text
Purification
Purified
Antibody Clonality
Recombinant Monoclonal
Storage Note
Store at 4⁰C for up to 3 months. Note, this antibody is provided without added preservatives, it is therefore recommed this antibody be handled under sterile conditions. For longer storage, aliquot and store at -20⁰C.
Application Notes
This nanobody was linked to an anti-GFP VHH via their C termini to create a bispecific antibody capable of targeting both GFP and MHC class II Molecules; the VHH7-GFP bispecific construct effectively targeted B cells and facilitated the uptake of GFP by these cells, as indicated by a flow cytometry (FC) analysis that showed that most CD19+ cells were GFP+, indicating successful capture of GFP in vivo. The same bispecific antibody was used to stain B cells in mouse lymph node cells, as observed using FC. This nanobody was also used to C-terminally conjugate human IL2 and IFN-α to anti-GFP, demonstrating the general applicability of the approach for linking different entities (Witte et al., 2012; PMID: 22778432). This nanobody was used as a control in a competition assay, where it was compared to a panel of NP-specific VHHs and used to block recombinant NP before immunoprecipitation (IP) (Ashour et al., 2015; PMID: 25540369). As part of its characterization, this nanobody's Ka, Kd, and KD were evaluated for polymorphic MHCII variants through binding experiments. Also, its binding capacity to recombinant MHCII-CLIP was measured by surface plasmon resonance (SPR). A fluorescently labeled variant of this nanobody was used to track the internalization of VHH-receptor complexes and acidic subcellular compartments. This nanobody was used in vivo to investigate its effects on immune responses and antibody production; it was found to activate CD8- dendritic cells, leading to stronger CD4 T cell proliferation than other antibodies tested (DC13 and DC20). This nanobody effectively delivered proteins or peptides to antigen-presenting cells, generating humoral immunity; fusion of antigens to this nanobody was found to enhance the immune response compared to other delivery methods - mice immunized with this nanobody fused to antigens such as GFP, yeast ubiquitin, OBI-17mer peptide, or influenza HA stem exhibited potent humoral responses, which were further enhanced by the dimeric version of this nanobody. VHH7-H3N2 HA212-63 immunization improved protection against influenza infection (Duarte et al., 2016; PMID: 27821668).
Short Description
This chimeric rabbit antibody was made using the variable domain sequences of the original Alpaca VHH format, for improved compatibility with existing reagents, assays and techniques.
AB04080-23.159-BT Datasheet
SUPPORT
outstanding technical support
PRODUCT
we offer a full product guarantee
DELIVERY
we offer free delivery to UK universities and non profit organisations